Upstream & Downstream Processing

Sartorius plans $500m+ CAPEX and eyes M&A opportunities in 2023

Sartorius invested €593 ($647) million in its global capacities in 2022 and says it is planning similar this year. For the full year 2022, Sartorius reported total sales of €4.17 billion, representing a 21% increase on the previous year. The firm’s Bioprocess Solutions business pulled in €3.32 billion of this and saw a 22% growth year-on-year. The firm reiterated how the skew of COVID-19 related revenues and demand normalization will drive down sales going forward, with CEO Joachim Kreuzburg forecasting…

TTP spins-out Cellular Origins to tackle CGT scalability

Independent technology and product development company TTP  announced the launch of spin-out company Cellular Origins during Advanced Therapies Week in Miami, Florida. TTP launched Cellular Origins to develop a commercial manufacturing platform that will enable biopharmaceutical companies to increase scale dramatically for advanced cell and gene therapy (CGT) production, addressing the difficulties that developers have in meeting manufacturing demand. Matthew Carr, head of life sciences at TTP, said, “We have every confidence that Cellular Origins will deliver on its mission…

Post-COVID bioprocess destocking but vendors optimistic for 2023

Vendors are feeling the economic impact of dwindling COVID-related bioproduction, but Thermo Fisher and Danaher remain unfazed, the firms said at JPM 2023. Many bioprocess vendors reported falling orders in the latter half of 2022 as biopharma reduced stock orders for vaccine and therapeutics following two years of unprecedented pandemic-related growth. This bioprocess destocking dynamic – described by some as a “swift normalization of demand” – was brought up at this week’s JP Morgan Healthcare Conference in San Francisco but…

Thermo Fisher to employ 5kL single-use bioreactor for Aslan’s eczema mAb

Aslan Pharmaceuticals has contracted Thermo Fisher to produce its atopic dermatitis candidate eblasakimab. Aslan’s lead candidate eblasakimab is being developed to treat atopic dermatitis (AD), the most common form of eczema. The monoclonal antibody (mAb) targets the IL-13 receptor α1 subunit (IL-13Rα1), which prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13), the key drivers of inflammation, central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin. The agreement will see…

MilliporeSigma bolsters bioreactor offering with Erbi buy

The acquisition of Erbi Biosystems will enable MilliporeSigma to offer a full range of bioreactors ranging from 2 ml to 2,000 L, says firm.   MilliporeSigma – the life sciences division of Germany’s Merck KGaA – has acquired Massachusetts-based firm Erbi for an undisclosed fee. According to the bioprocess vendor and contract development and manufacturing organization (CDMO), Erbi’s 2 ml micro-bioreactor platform, Breez, will strengthen its upstream portfolio.  The Breez bioreactors operate by using miniaturized valves, filters, mixing, pumps, and sensors to perform…

Thermo Fisher launches AAV tech to reduce costs by 50%

Thermo Fisher Scientific has introduced the Gibco CTS adeno-associated virus (AAV)- MAX Helper Free production system, which it says can save time and reduce costs by 50%. According to the firm, the all-in-one solution production system is “the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.” Additionally, Thermo says that the system has been designed to meet both clinical and commercial demands of AAV-based gene therapies, as well as bringing products to market…

Thermo Fisher cutting jobs at NY cell culture media plant

The Grand Island facility, fresh from a $76 million expansion, will see a “limited” reduction in staff as Thermo Fisher adjusts to “stay current with the market.” Whether in liquid or powder form, Cell culture media is an integral part of producing biologics and vaccines, and an essential factor in cell viability, performance, and yield. As a supplier of such media, Thermo Fisher has undergone a $76 million expansion at its Grand Island, New York cell culture media facility, which…

HPNE launches modular and customizable TFF system

The off-the-shelf OptiMaxx tangential flow filtration (TFF) system “brings open architecture” to downstream bioprocessing, says High Purity New England (HPNE). The Rhode Island-based single-use equipment supplier unveiled OptiMaxx last week to offer biomanufacturers a simpler and more customizable TFF system. “OptiMaxx brings open architecture, the versatility of being able to configure it for any processing needs,” Emily Peterson, BD manager of the OptiMaxx product line told this publication. “Whether it’s single-use or multi-use or using virtually any sensor or filter…

Danaher cites COVID ebb and bioprocess productivity for drop in orders

As a further sign of a post-COVID normalization in bioprocess demand, Danaher Corporation has reported a 20% drop in orders for Cytiva and Pall in Q3. Danaher Corporation does not break down its financials across its various business types, but speaking on its Q3 financial call the firm said its Biotechnology Group – the recently combined bioprocess offerings of Cytiva and Pall – had a strong quarter. Part of this is due to the continued demand for bioprocessing tools and…

Sartorius: Fall in order intake a sign of swift normalization post-COVID

Sartorius has reported a “swift normalization of demand” following two years of unprecedented pandemic-related growth combined with supply chain disruption. For the first nine months 2022, Sartorius pulled in sales of €3.11 billion ($3.05 billion) across its businesses, up 23.2% on the same period last year. The majority – €2.47 billion – came from its bioprocess solutions business, up 24.3 %, though order intake over the period dropped 10.3% year-on-year to €2.45 billion. “The development of the bioprocessing business was…